Last edition
News about " mutant CALR"
Damora Therapeutics Launches Global Phase 1/1b Trial of DMR-001 for mutCALR-Driven Blood Cancers
Damora Therapeutics initiates the global CLARITY-101 clinical trial to assess DMR-001, a novel mutation-targeted therapy designed to address the underlying cause of mutCALR-driven blood disorders.
Mutant CALR | 07/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members